Want to see UPC full AI Analyst Report?
UPC Stock Chart & Stats
$4.22
-$0.02(-3.13%)
At close: 4:00 PM EST
$4.22
-$0.02(-3.13%)
Day’s Range― - ―
52-Week Range$2.00 - $17.96
Previous CloseN/A
Volume250.22K
Average Volume (3M)955.25K
Market Cap
$3.38M
Enterprise Value-$22.70M
Total Cash (Recent Filing)$33.59M
Total Debt (Recent Filing)$9.26M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Aug 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-945.09
Shares Outstanding631,761
10 Day Avg. Volume2,486,504
30 Day Avg. Volume955,249
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00082
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-6.72
Enterprise Value/Revenue-1.27
Enterprise Value/Gross Profit-3.60
Enterprise Value/Ebitda7.77
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and modest absolute debt give the company a durable financial cushion versus peers. Manageable indebtedness reduces bankruptcy risk and preserves flexibility to fund R&D, M&A or weather operating losses over the next several quarters without immediate refinancing pressure.
Improving Gross Margin And Lower Cash BurnA material rebound in gross margin alongside a smaller operating cash outflow signals better cost absorption or mix shift. If sustained, margin improvement reduces the revenue level needed for breakeven and supports a multi‑quarter path toward restoring operating leverage and improving cash conversion.
Pipeline Expansion Via IP AcquisitionThe stock-for-IP deal adds patents across age‑related, neurodegenerative, cardiovascular and drug delivery areas, expanding long‑term product options without immediate cash outlay. Broader IP can strengthen future R&D, licensing or partnering opportunities and diversify growth vectors.
Bears Say
Multi-year Revenue Decline And Sustained LossesA persistent fall in top line combined with four consecutive years of net losses indicates structural demand or commercialization issues. Continued revenue shrinkage undermines scale economics, makes fixed costs harder to cover, and lengthens the timeline to sustainable profitability absent a clear revenue recovery.
Weak And Negative Cash GenerationRepeated negative operating and free cash flows show the business currently consumes cash rather than funds itself. That pattern creates reliance on external financing or equity issuance, raising dilution risk and constraining sustained investment in clinical development or commercialization over multiple quarters.
Concentrated Voting Control By CEOVery high insider voting power concentrates decision authority and can weaken independent oversight. Entrenchment risk may reduce minority shareholder influence on strategy, capital allocation or corporate governance, potentially leading to decisions favoring controller interests over long-term shareholder value.
Universe Pharmaceuticals News
UPC FAQ
What was Universe Pharmaceuticals’s price range in the past 12 months?
Universe Pharmaceuticals lowest stock price was $2.00 and its highest was $17.96 in the past 12 months.
What is Universe Pharmaceuticals’s market cap?
Universe Pharmaceuticals’s market cap is $3.38M.
When is Universe Pharmaceuticals’s upcoming earnings report date?
Universe Pharmaceuticals’s upcoming earnings report date is Aug 03, 2026 which is in 23 days.
How were Universe Pharmaceuticals’s earnings last quarter?
Universe Pharmaceuticals released its earnings results on Feb 03, 2026. The company reported -$0.688 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.688.
Is Universe Pharmaceuticals overvalued?
According to Wall Street analysts Universe Pharmaceuticals’s price is currently Overvalued.
Does Universe Pharmaceuticals pay dividends?
Universe Pharmaceuticals does not currently pay dividends.
What is Universe Pharmaceuticals’s EPS estimate?
Universe Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Universe Pharmaceuticals have?
Universe Pharmaceuticals has 631,761 shares outstanding.
What happened to Universe Pharmaceuticals’s price movement after its last earnings report?
Universe Pharmaceuticals reported an EPS of -$0.688 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.721%.
Which hedge fund is a major shareholder of Universe Pharmaceuticals?
Currently, no hedge funds are holding shares in UPC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Universe Pharmaceuticals
Universe Pharmaceuticals Inc. (UPC) operates as a pharmaceutical enterprise primarily focused on the Chinese market. The company specializes in the production, promotion, and sale of products derived from traditional Chinese medicine (TCM). These remedies are designed to address common chronic health issues prevalent among the elderly, promoting physical well-being and longevity, in addition to offering medications for cold and flu symptoms. Beyond its own manufactured goods, UPC also functions as a distributor and vendor for a diverse range of third-party products. This extensive portfolio includes biomedical drugs, medical instruments, traditional Chinese medicine 'pieces' (raw ingredients), and various dietary supplements. Its clientele spans across the healthcare sector, encompassing other pharmaceutical companies, hospitals, clinics, and major drugstore chains. Established in 2019, the company's operations are headquartered in Ji'An, China, and it functions as a subsidiary of Sununion Holding Group Limited.
Technical Analysis
China Pharma Holdings
―
RedHill Biopharma
―
China SXT Pharmaceuticals
―
PainReform
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
Options Prices
Currently, No data available
---